Empagliflozin
Sold as Jardiance, Losugby, Aziempa, Tuerizin, Empagliflozin zydus, Stenit, Pemfeg, Inglyflo, Empagliflozin unicorn, Empagliflozin PD, Empamak, Empagliflozin ascend, Meglyzin, Ampoldo
(2S,3R,4R,5S,6R)-2-[4-Chloro-3-[[4-[(3S)-oxolan-3-yl]oxyphenyl]methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol
Drag to rotate. Structure from PubChem CID 11949646.
Background
Registration
- Applicants
- 11
- Registrations
- 27
- Schedule source
- Consolidated Schedules 06 July 2026
Applicants and registrations
| Applicant | Brands | Dosages | Registrations | Schedule | Leaflets |
|---|---|---|---|---|---|
| Ingelheim Pharmaceuticals (Pty) Ltd û Ferndale | Jardiance | 10 mg, 25 mg | 480411, 481380 | S4 | None |
| Ruby Pharmaceuticals (Pty) Ltd | Losugby | 10 mg, 25 mg | 540649, 540650 | S4 | None |
| Austell Pharmaceuticals (Pty) Ltd | Aziempa | 10mg, 25mg | 540651.649, 540652.65 | S4 | None |
| Zydus Healthcare (Pty) Ltd | Tuerizin, Empagliflozin zydus | 10, 25 | 550628, 550629, 550630.628, 550631.629 | S4 | None |
| Lebasi Pharmaceuticals (Pty) Ltd | Stenit, Pemfeg | 10, 25 | 560281, 560282.280, 560283.281 | S4 | None |
| Dr Reddyæs Laboratories (Pty) LtdCertificate held by Dr. Reddy’s Laboratories (Pty) Ltd. | Inglyflo | 10, 25 | 560284, 560285 | S4 | PIPIL |
| Unicorn Pharmaceuticals (Pty) Ltd | Empagliflozin unicorn | 10, 20 | 560700, 560701 | S4 | None |
| Pharma Dynamics (Pty) Ltd | Empagliflozin PD | 10 mg, 25 mg | 560973, 560974 | S4 | None |
| Macleods Pharmaceuticals SA (Pty) Ltd | Empamak | 10, 25 | 561147, 561148 | S4 | None |
| Ascend Laboratories (Pty) Ltd | Empagliflozin ascend | 10 mg, 25 mg | 570256, 570257 | S4 | None |
| Hetero Drugs South Africa (Pty) Ltd | Meglyzin, Ampoldo | 10, 25 | 590387, 590388, 590389.387, 590390.388 | S4 | None |
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Jardiance 25 MG EACH TABLET CONTAINS EMPAGLIFLOZIN 25,0 mg | 25 mg | 48041148/21.2/0411 | Registered | S4 | None |
| Jardiance 10 MG EACH TABLET CONTAINS EMPAGLIFLOZIN 10,0 mg | 10 mg | 48138048/21.2/1380 | Registered | S4 | None |
| Losugby 10 MG EACH TABLET CONTAINS: EMPAGLIFLOZIN 10,0 mg | 10 mg | 54064954/21.2/0649 | Registered | S4 | None |
| Losugby 25 MG EACH TABLET CONTAINS: EMPAGLIFLOZIN 25,0 mg | 25 mg | 54065054/21.2/0650 | Registered | S4 | None |
| Aziempa 10mg EACH TABLET CONTAINS: EMPAGLIFLOZIN 10,0 mg | 10mg | 540651.64954/21.2/0651.649 | Registered | S4 | None |
| Aziempa 25mg EACH TABLET CONTAINS: EMPAGLIFLOZIN 25,0 mg | 25mg | 540652.6554/21.2/0652.650 | Registered | S4 | None |
| Tuerizin 10 EACH TABLAET CONTAINS EMPAGLIFLOZIN 10,0 mg | 10 | 55062855/21.2/0628 | Registrered | S4 | None |
| Tuerizin 25 EACH TABLET CONTAINS EMPAGLIFLOZIN 25,0 mg | 25 | 55062955/21.2/0629 | Registrered | S4 | None |
| Empagliflozin 10 zydus EACH TABLET CONTAINS EMPAGLIFLOZIN 10,0 mg | 10 | 550630.62855/21.2/0630.628 | Registrered | S4 | None |
| Empagliflozin 25 zydus EACH TABLET CONTAINS EMPAGLIFLOZIN 25,0 mg | 25 | 550631.62955/21.2/0631.629 | Registrered | S4 | None |
| Stenit 25 EACH TABLET CONTAINS EMPAGLIFLOZIN 25,0 mg | 25 | 56028156/21.2/0281 | Registered | S4 | None |
| Pemfeg 10 EACH TABLET CONTAINS EMPAGLIFLOZIN 10,0 mg | 10 | 560282.28056/21.2/0282.280 | Registered | S4 | None |
| Pemfeg 25 EACH TABLET CONTAINS EMPAGLIFLOZIN 25,0 mg | 25 | 560283.28156/21.2/0283.281 | Registered | S4 | None |
| Inglyflo 10 EACH TABLET CONTAINS EMPAGLIFLOZIN 10,0 mg | 10Film-coated tablets | 56028456/21.2/0284Approved 17 February 2026 | Registered | S4 | PIPIL |
| Inglyflo 25 EACH TABLET CONTAINS EMPAGLIFLOZIN 25,0 mg | 25Film-coated tablets | 56028556/21.2/0285Approved 17 February 2026 | Registered | S4 | PIPIL |
| Empagliflozin 10 unicorn EACH TABLET CONTAINS EMPAGLIFLOZIN 10,0 mg | 10 | 56070056/21.2/0700 | Registered | S4 | None |
| Empagliflozin 20 unicorn EACH TABLET CONTAINS EMPAGLIFLOZIN 20,0 mg | 20 | 56070156/21.2/0701 | Registered | S4 | None |
| Empagliflozin 10 MG PD Each Tablet contains: Empagliflozin 10,0 mg | 10 mg | 56097356/21.2/0973 | Registered | S4 | None |
| Empagliflozin 25 MG PD Each Tablet contains:Emagliflozin 25,0 mg | 25 mg | 56097456/21.2/0974 | Registered | S4 | None |
| Empamak 10 EACH TABLET CONTAINS EMPAGLIFLOZIN 10,0 mg | 10 | 56114756/21.2/1147 | Registered | S4 | None |
| Empamak 25 EACH TABLET CONTAINS: EMPAGLIFLOZIN 10,0 mg | 25 | 56114856/21.2/1148 | Registered | S4 | None |
| Empagliflozin 10 MG ascend EACH TABLET CONTAINS: EMPAGLIFLOZIN 10,0 mg | 10 mg | 57025657/21.2/0256 | Registered | S4 | None |
| Empagliflozin 25 MG ascend EACH TABLET CONTAINS: EMPAGLIFLOZIN 25,0 mg | 25 mg | 57025757/21.2/0257 | Registered | S4 | None |
| Meglyzin 10 EACH TABLET CONTAINS: EMPAGLIFLOZIN 10,0 mg | 10 | 59038759/21.2/0387 | Registered | S4 | None |
| Meglyzin 25 EACH TABLET CONTAINS: EMPAGLIFLOZIN 25,0 mg | 25 | 59038859/21.2/0388 | Registered | S4 | None |
| Ampoldo 10 EACH TABLET CONTAINS: EMPAGLIFLOZIN 10,0 mg | 10 | 590389.38759/21.2/0389.387 | Registered | S4 | None |
| Ampoldo 25 EACH TABLET CONTAINS: EMPAGLIFLOZIN 25,0 mg | 25 | 590390.38859/21.2/0390.388 | Registered | S4 | None |
Regulatory status
Where S4 sits on the scale
Prescription-only medicine.
Schedule 4 covers most ordinary prescription medicines. You need a prescription from an authorised prescriber, such as a doctor or dentist, and a pharmacist dispenses it. Its price, name, pack size and strength can still be told to the public, as long as nothing links it to what it treats.
Schedule S4, matched to the Consolidated Schedules by ingredient, confidence high.
Who may supply: A pharmacist dispensing against a written or verbal prescription from an authorised prescriber; a veterinarian, who may also prescribe, compound or dispense it directly; a medical practitioner or dentist, who may prescribe it and may compound or dispense it directly only if licensed under section 22C(1)(a); manufacturers and wholesalers may supply people who may lawfully possess it; and, for animal treatment, a person practising a para-veterinary profession, on a veterinarian's written or verbal instruction.
Consolidated Schedules listings for Empagliflozin
S4: Empagliflozin
Consolidated Schedules 06 July 2026, line 6176
Pharmacological class: Oral hypoglycaemics. (class 21.2)
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
SAHPRA documents
Schedule Verification
Inglyflo 10, Dr Reddyæs Laboratories (Pty) Ltd is scheduled S4 in its official SAHPRA documents, read with 90% confidence.
These documents are provided by SAHPRA for informational purposes. Always consult with a healthcare professional for medical advice.